Description
Anrukinzumab is a humanized monoclonal antibody targeting IL-13 that inhibits attachment of IL-13 to IL-4R, thus interrupting IL-13 signaling. It is indicated for the treatment of asthma.
Principle:
The method employs the quantitative sandwich enzyme immunoassay technique. Antibodies to Anrukinzumab are pre-coated onto microwells. Samples and standards are pipetted into microwells and human Anrukinzumab present in the sample are bound by the capture antibody. Then, a HRP (horseradish peroxidase) conjugated anti-Anrukinzumab antibody is pipetted and incubated. After washing microwells in order to remove any non-specific binding, the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the amount of Anrukinzumab in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.
If you have published a paper by using any of our ELISA since 01/01/2023, kindly fill out the “Krishgen Publication Reward Application Form” with complete information and send it by at email: info@krishgen.com, with the subject “Krishgen Publication Reward”. We will get back to you with the Amazon / Krishgen Credit Reward after we confirm it ASAP!